Genmab A/S at Morgan Stanley Global Healthcare Conference Transcript
All right. Perfect. I think we are ready to go. Good morning, everybody. Thanks for joining us for the next session. I'm Matthew Harrison, one of the biotech analysts here at Morgan Stanley. Very pleased to have Genmab with us this morning.
Briefly before we get started, I need to read a disclosure statement. Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures appear on the Morgan Stanley public website at morganstanley.com/researchdisclosures.
So with that, I'm pleased to have Jan van de Winkel, the CEO of Genmab; and Anthony Pagano, who is the CFO. Jan, I thought maybe a good place to start would be to talk about epco and maybe just update people on where we are in terms of filing and path to market there.
Questions & Answers
/-- -
Thanks for having us here today. We
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
